• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!

Purdue University — Imatinib Trial for Drug-Resistant Malaria

Visit Grantee Site
  • Portfolio Area: Human Health and Wellbeing
  • Focus Area: Scientific Research
  • Organization Name: Purdue University
  • Amount: $600,000

  • Award Date: September 2022

Table of Contents

    Jun Yang, from left, a former doctoral student and researcher in the Low research group, and Philip Low are shown in the group’s lab. (Purdue News Service photo/David Umberger)

    Open Philanthropy recommended a grant of $600,000 over three years to Purdue University to support a phase III trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Vietnam. This research will be coordinated by Professor Philip Low, who previously organized a successful phase II trial of imatinib.

    This falls within our focus area of scientific research, specifically within our interest in advancing human health and wellbeing.

    Related Items

    • Human Health and Wellbeing

      University of Georgia — Malaria Research (2023)

      Open Philanthropy recommended a grant of $192,925 over three years to the University of Georgia to support research on Plasmodium vivax, which is one of the parasite species...

      Read more
    • Human Health and Wellbeing

      Washington University in St. Louis — Omega-3 Trial for Pregnant Women

      Open Philanthropy recommended a grant of $1,500,000 over three years to Washington University in St. Louis to support a randomized controlled trial in Sierra Leone, led by Dr. Mark...

      Read more
    • Human Health and Wellbeing

      Foundation for Professional Development Fund — Syphilis Genome Sequencing

      Open Philanthropy recommended a grant of $229,080 over three years to the Foundation for Professional Development Fund to support their collaboration with the University of Southern California and...

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    • Stay Updated
    Mailing Address
    Open Philanthropy
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    © Open Philanthropy 2022 Except where otherwise noted, this work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License. If you'd like to translate this content into another language, please get in touch!